| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Chen,Chang-Hui | Chairman | 10.29% | |
| Xie,Qi-Hong | Director | 9.78% | |
| Ma,Nan-Rong | Director | 9.16% | ISTAT BIOMEDICAL CO., LTD. |
| Huang,Cui-Ping | Independent Director | 0.00% | |
| Liu,Qiu-Juan | Independent Director | 0.00% | |
| Hong,Zhe-Zhang | Independent Director | 0.00% | |
| Chen,Yu-Xian | Independent Director | 0.00% |
Change Capital to 600,000,000
2023/12/27
Change Company Name to HAN DOCTOR TECHNOLOGY CO., LTD. (FORMER NAME: HAN DOCTOR TECHNOLOGY CO., LTD.)
2023/07/11
Change Company Name to HAN BIOMEDICAL INC.
2023/07/11
Change Company Name to HAN DOCTOR TECHNOLOGY CO., LTD. (FORMER NAME: HAN DOCTOR TECHNOLOGY CO., LTD.)
2023/06/21
Change Company Name to HAN BIOMEDICAL INC.
2023/06/21
Change Company Name to HAN DOCTOR TECHNOLOGY CO., LTD. (FORMER NAME: HAN DOCTOR TECHNOLOGY CO., LTD.)
2022/09/22
Change Company Name to HAN BIOMEDICAL INC.
2022/09/22
Change Capital to 300,000,000
2017/09/08
Change Capital to 100,000,000
2014/12/08
Change Capital to 30,000,000
2013/06/14
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 52,478 | 96,842 | 93,984 |
| Operating cost | 15,838 | 26,384 | 33,387 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 36,640 | 70,458 | 60,597 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 36,640 | 70,458 | 60,597 |
| Operating expenses | 25,326 | 45,022 | 36,813 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 11,314 | 25,436 | 23,784 |
| Non-operating income and expenses | 1,804 | 1,696 | 425 |
| Net profit (loss) before tax | 13,118 | 27,132 | 24,209 |
| Income tax expense (benefits) | 2,705 | 5,590 | 5,467 |
| Net profit (loss) of ongoing business for the current period | 10,413 | 21,542 | 18,742 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 10,413 | 21,542 | 18,742 |
| Other comprehensive profit (loss), net | 13 | 36 | - |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 10,426 | 21,578 | 18,742 |
| Net profit (loss) attributable to owners of parent company | 10,413 | 21,542 | - |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | 0 | - |
| Net profit (loss) attributable to non-controlling interests | - | 0 | - |
| Comprehensive profit (loss) attributable to owners of parent company | 10,426 | 21,578 | - |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | 0 | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | 0 | - |
| Basic earnings per share (yuan) | 0 | 1 | 1 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 13,957 | 30,896 | - |
| Net cash inflows (outflows) from investing activities | -450 | -79,317 | - |
| Net cash inflow (outflow) from financing activities | 23,760 | -4,461 | - |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 13 | 36 | - |
| Increase (decrease) in cash and cash equivalents in the current period | 37,280 | -52,846 | - |
| Beginning balance of cash and cash equivalents | 79,631 | 132,477 | - |
| Ending balance of cash and cash equivalents | 116,911 | 79,631 | - |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 257,203 | 211,909 | 181,209 |
| Non-current asset | 11,849 | 17,594 | 31,012 |
| Total asset | 269,052 | 229,503 | 212,221 |
| Current liability | 32,838 | 20,812 | 20,863 |
| Non-current liability | 978 | 1,205 | 5,450 |
| Total liability | 33,816 | 22,017 | 26,313 |
| share capital | 189,785 | 172,510 | 156,827 |
| Equity - secruity token | - | - | - |
| capital reserve | 25,112 | 7,812 | 7,812 |
| retained earning | 20,290 | 27,128 | 21,269 |
| Other equity | 49 | 36 | - |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 235,236 | 207,486 | - |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 235,236 | 207,486 | 185,908 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | - |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 12 | 12 | 11 |
